side-area-logo

News and Events

Eloxx Pharmaceuticals Announces Expansion of Intellectual Property Estate for ELX-02 with Newly Granted Patent in Europe

Sevion Therapeutics, Inc. (OTCQB:SVON) and Eloxx Pharmaceuticals Ltd.,, today announced that the European Patent Office (EPO) has granted a patent covering the Company's lead product candidate, ELX-02, as well as…

Eloxx Pharmaceuticals Appoints Gregory Weaver as Chief Financial Officer

Sevion Therapeutics, Inc. (OTCQB:SVON) and Eloxx Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company developing novel small molecule medicines for genetic diseases caused by nonsense mutations, today announced the appointment of Gregory…

Eloxx Pharmaceuticals Expands Management Team to Support Rapid Development of Lead Drug Candidate ELX-02 for the Treatment of Rare Genetic Diseases

Sevion Therapeutics, Inc. (OTCQB: SVON) and Eloxx Pharmaceuticals Ltd., a clinical stage biopharmaceutical company developing therapeutics for genetic diseases caused by nonsense mutations, today announced the expansion of its development…

Eloxx Pharmaceuticals Secures US$8 Million Investment from LSP, Increasing Total Raised in Series C to US$38 million

Sevion Therapeutics, Inc. (OTCQB: SVON) and Eloxx Pharmaceuticals Ltd., a clinical stage company developing therapeutics for genetic diseases caused by nonsense mutations, announced today the closing of additional US$8 million…

Eloxx Pharmaceuticals Receives a US$6 Million Investment from KIP and DCS to Advance a Novel Disease-Modifying Therapy Targeting Genetic Diseases Including Cystic Fibrosis

Today, Korea Investment Partners (KIP), DSC Investments, Sevion Therapeutics, Inc. (OTCQB:SVON) and Eloxx Pharmaceuticals Ltd, a clinical stage company developing therapeutics for genetic diseases caused by nonsense mutations, announce a…

Catalyst CEL Fund invests in genetic drug development company Eloxx

Catalyst CEL Fund (the “Fund”) is pleased to announce the investment in Eloxx Pharmaceuticals Limited (“Eloxx” or the “Company”), a clinical stage company developing therapeutics for genetic diseases caused by…

Eloxx Pharmacueticals Receives A US$5 Million Investment from Quark Venture and GF Securities to Advance A Novel Disease-Modifying Therapy Targeting Genetic Diseases

Today, Quark Venture Inc. and GF Securities announced a $US5 million investment Eloxx Pharmaceuticals through their Global Health Science Fund.

Sevion Therapeutics Inc. and Eloxx Pharmaceuticals Ltd Announce the Entering into of an Acquisition Transaction

Sevion Therapeutics, Inc., (OTCQB: SVON) and Eloxx Pharmaceuticals Ltd., a clinical stage company developing therapeutics for genetic diseases caused by non-sense mutations, announced today the signing of a definitive agreement…

Eloxx Pharmaceuticals Announces Orphan Drug Designation in the U.S. and Europe for ELX-02 in Mucopolysacchardisis Type 1 (MPS 1)

Eloxx Pharmaceuticals, a biotechnology company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations, announced today that the U.S. Food and…